期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

先天性肾上腺皮质增生症(失盐型)1例报告

A Case Report on Congenital Adrenal Hyperplasia(Salt Losing Type)
下载PDF
导出
摘要 1病例资料患儿男,28 d,因＂呕吐、鼻塞3 d＂入院,入院时症见：恶心,吐奶,鼻塞,鼻流清涕,打喷嚏,无咳嗽、呻吟、吐沫,无尖叫、抽搐。纳奶欠佳,出汗多,哭时少泪,夜寐欠安,易惊跳,大便偏稀,黄绿色,5-6次/d,小便较前稍减少。第2胎第2产,胎龄40^＋5周,顺产娩出,出生体质量3.9 kg,羊水量中,羊水清亮,无胎膜早破,脐带正常,胎盘正常,否认窒息史,
作者 李娇艳 张康宁 董晓斐
机构地区 湖南中医药大学第一附属医院 湖南中医药大学
出处 《湖南中医药大学学报》 CAS 2016年第5期77-78,共2页 Journal of Hunan University of Chinese Medicine
关键词 先天性肾上腺皮质增生症 失盐型 病例报告 congenital adrenal hyperplasia salt losing type case reports
分类号 R692.1 [医药卫生—泌尿科学]
  • 相关文献

参考文献7

  • 1Trapp CM, Oberfield SF Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update [J]. Steroids, 2012,77(4):342-546.
  • 2Kochar IP, Jindal R. Diagnosis and management of congenital adrenal hyperplasia in the child and adolescent [J]. Apollo Medicine,2011,8(4):261-265.
  • 3胡亚美 江载芳.诸福棠实用儿科学[M]第7版[M].北京:人民卫生出版社,2002.1514.
  • 4Arlt W, Allolio B. Adrenal insufficiency [J]. Lancet,2003,361 (9372):1 881-1 893.
  • 5Quinkler M, Meyer 13, Oelkers W, et at Renalinactivatio~ mineral ocorticoid generation, and 1 lbeta-hydroxysteroid dehydrogenase inhi-bition amefiorate the antimineralocorticoid effect of proges- terone in vivo[J]. J Clin Endoerinol Metab, 2003,88(8):3 767- 3 772.
  • 6Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic Mope- ciain the pediatric population: a retrospective review of 57 pa- tients[J]. Br J Dermatol,2010,163(2):378-385.
  • 7肖慧文(综述),马华梅(审校).先天性肾上腺皮质增生症21羟化酶缺乏患者的生长与最终身高影响因素[J].国际儿科学杂志,2011,38(3):210-215. 被引量：8

二级参考文献32

  • 1韩蓓,韩连书,叶军,邱文娟,顾学范.21羟化酶缺乏症患者最终身高影响因素探讨[J].中华儿科杂志,2004,42(11):865-866. 被引量：3
  • 2田玉梅,叶军,韩连书,邱文娟,顾学范.不同初治年龄对先天性肾上腺皮质增生症患儿发育的影响[J].中国实用儿科杂志,2006,21(4):272-273. 被引量：16
  • 3Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21- hydroxylase deficiency. J Clin Endocrinol Metab, 2003,88 ( 12 ) : 5680-5688.
  • 4Hargitai G,Solyom J, Battelino T,et al. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a muhicenter study. Horm Res, 2001,55 (4) : 161-171.
  • 5Eugster EA, Dimeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr, 2001,138 ( 1 ) :26-32.
  • 6Brunelli VL, Russo G, Bertelloni S, et al. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. J Pediatr Endocrinol Metab,2003,16 Suppl 2:277-283.
  • 7Bortfig W,Bechtold S,Schmidt H,et al. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab ,2007,92(5 ) : 1635-1639.
  • 8Migeon CJ, Wisniewski AB. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations. Endocrinol Metab Clin North Am,2001,30 ( 1 ) : 193- 206.
  • 9Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, et al. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clin Endocrinol (Oxf), 2002,57 ( 5 ) :669-676.
  • 10Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab, 2001,86 (7) :3070-3078.

共引文献1207

湖南中医药大学学报
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部